Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Latigo BiotherapeuticsLTGO -13.10%8 Market Cap is $0.00 Mil as of Aug. 10, 2026. GuruFocus rates LTGO with a GF Score™ of 8/100. Among 1,419 Biotechnology companies, Latigo Biotherapeutics ranks worse than 70472.09% on this metric.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Latigo Biotherapeutics's Enterprise Value for Today is $0.00 Mil.
Latigo Biotherapeutics (NAS:LTGO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Latigo Biotherapeutics Market Cap Chart
Latigo Biotherapeutics Annual Data
Trend
Dec24
Dec25
Market Cap
0.00
0.00
Latigo Biotherapeutics Semi-Annual Data
Dec24
Dec25
Market Cap
0.00
0.00
LTGO vs : Market Cap Comparison
For the Biotechnology subindustry, Latigo Biotherapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Latigo Biotherapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Latigo Biotherapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Latigo Biotherapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Latigo Biotherapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Latigo Biotherapeutics (LTGO) has a Market Cap of $0.00 Mil as of Aug. 10, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Latigo Biotherapeutics and its competitors. According to the industry distribution chart, Latigo Biotherapeutics ranks #999999 out of 1419 companies in the Biotechnology industry.
Is Latigo Biotherapeutics' Market Cap too high?
Latigo Biotherapeutics' current Market Cap is $0.00 Mil. Based on the distribution chart, Latigo Biotherapeutics ranks #999999 out of 1419 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Latigo Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Latigo Biotherapeutics' Market Cap compare to ?
According to the Biotechnology industry distribution chart, Latigo Biotherapeutics ranks #999999 out of 1419 companies for Market Cap. This places Latigo Biotherapeutics in the lower half of its industry. The industry median Market Cap is 116.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.54, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Latigo Biotherapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 116.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Latigo Biotherapeutics's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Latigo Biotherapeutics stock overvalued right now?
Latigo Biotherapeutics (LTGO) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Latigo Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Latigo Biotherapeutics (LTGO), the current Market Cap is $0.00 Mil as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
8GF Score
Get the complete analysis for LTGO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTGO has been successfully added to your 
